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The	  History	  and	  Fate	  of	  the	  “Gold	  Standard”	  	  David	  S.	  Jones	  and	  Scott	  H.	  Podolsky	  	  	   For	  the	  past	  half	  century,	  physicians	  and	  clinical	  researchers	  have	  remained	  confident	  that	  randomized	  controlled	  trials	  (RCTs)	  provide	  the	  most	  rigorous	  test	  of	  preventive,	  diagnostic,	  and	  therapeutic	  interventions.	  They	  are	  ubiquitously	  referred	  to	  as	  the	  “gold	  standard”	  of	  empiric	  biomedical	  investigation,	  to	  the	  point	  where	  this	  status	  is	  often	  presented	  as	  a	  self-­‐evident	  starting	  point	  in	  diagnostic	  or	  therapeutic	  evaluation.	  However,	  this	  status	  has	  long	  been	  contested,	  ever	  more	  so	  now	  with	  the	  emergence	  of	  “big	  data,”	  randomized	  registry	  trials,	  and	  other	  modes	  of	  knowledge	  production	  in	  medicine.	  In	  an	  era	  of	  increasing	  methodological	  self-­‐reflection,	  it	  is	  useful	  to	  step	  back	  and	  examine	  how	  and	  when	  RCTs	  became	  the	  gold	  standard	  and	  what	  our	  aspirations	  for	  gold	  standards	  reveal	  about	  our	  deeper	  medical	  identity.	  	   RCTs	  had	  a	  complicated	  pre-­‐history,	  entailing	  attempts	  to	  ensure	  equivalent	  active	  and	  control	  groups,	  the	  occasional	  blinding	  of	  researchers	  or	  subjects,	  and	  the	  development	  of	  statistical	  methods	  of	  comparison.	  	  They	  took	  on	  their	  recognizably modern	  form	  with	  the	  British	  Medical	  Research	  Council’s	  landmark	  1948	  trial	  of	  streptomycin	  for	  pulmonary	  tuberculosis.	  As	  statisticians	  and	  clinical	  pharmacologists	  attempted	  to	  make	  sense	  of	  the	  post-­‐Word	  War	  II	  pharmaceutical	  revolution,	  the	  power	  of	  RCTs	  seemed	  critical.	  When	  the	  1962	  amendments	  to	  the	  Food	  and	  Drug	  Administration	  mandated	  proof	  of	  efficacy	  through	  “well-­‐controlled”	  studies	  –	  namely,	  RCTs	  –	  prior	  to	  new	  drug	  approval,	  the	  United	  States	  government	  set	  the	  stage	  for	  the	  avalanche	  of	  pharmaceutical	  trials	  that	  followed.	  In	  Britain	  throughout	  the	  1960s	  and	  1970s,	  Archibald	  Cochrane	  advocated	  for	  the	  utility	  of	  RCT’s	  to	  sort	  therapeutic	  wheat	  from	  chaff.	  His	  work	  set	  the	  stage	  for	  such	  worldwide	  champions	  of	  rational	  therapeutic	  assessment	  as	  Thomas	  Chalmers,	  Iain	  Chalmers,	  David	  Sackett,	  and	  their	  colleagues.	  	   But	  when	  did	  RCT’s	  become	  the	  gold	  standard?	  The	  first	  instance	  we	  have	  found	  of	  the	  phrase	  “gold	  standard”	  to	  refer	  to	  RCTs	  came	  in	  the	  pages	  of	  the	  New	  England	  Journal	  of	  
Medicine	  in	  December	  1982,	  in	  an	  article	  written	  by	  Alvan	  Feinstein	  and	  Ralph	  Horwitz.	  This	  date	  surprised	  us	  (and	  many	  of	  our	  colleagues)	  as	  a	  very	  late	  date	  for	  the	  first	  usage.	  Despite	  extensive	  searching,	  we	  have	  found	  no	  earlier	  occurrence	  of	  “gold	  standard”	  in	  reference	  to	  RCTs.	  We	  are	  eager	  to	  be	  proven	  wrong,	  but	  until	  all	  textbooks,	  conference	  proceedings,	  journals,	  and	  archival	  collections	  have	  been	  digitized	  and	  made	  full-­‐text	  searchable,	  the	  gold	  standard	  of	  historical	  research	  itself	  remains	  elusive.	  Of	  interest,	  Feinstein	  and	  Horwitz	  described	  RCTs	  not	  as	  a	  gold	  standard	  that	  all	  research	  must	  strive	  to	  attain,	  but	  as	  an	  elusive	  ideal.	  Their	  special	  article	  was	  actually	  a	  brief	  in	  support	  of	  the	  rigorous	  conduct	  of	  other	  clinical	  epidemiological	  research	  designs.	  As	  they	  remarked,	  “epidemiological	  research	  has	  become	  increasingly	  important	  because	  it	  offers	  a	  substitute	  for	  the	  unattainable	  scientific	  gold	  standard	  of	  a	  randomized	  experimental	  trial.”	  	   Given	  these	  surprises,	  it	  is	  worth	  looking	  more	  closely	  at	  how	  and	  when	  the	  concept	  entered	  the	  medical	  literature.	  The	  phrase	  “gold	  standard”	  has	  a	  long	  pre-­‐history.	  It	  first	  appeared	  in	  Lancet	  in	  1870	  in	  a	  discussion	  of	  international	  coinage	  and	  efforts	  to	  restore	  the	  value	  of	  the	  guinea.	  Over	  the	  next	  sixty	  years	  it	  occurred	  repeatedly,	  in	  discussions	  of	  the	  actual	  gold	  standard:	  the	  technique	  of	  international	  finance	  that	  links	  the	  value	  of	  a	  nation’s	  currency	  to	  a	  set	  amount	  of	  gold,	  facilitating	  exchange	  between	  different	  
currencies.	  In	  the	  1930s	  “gold	  standard”	  gained	  a	  new	  usage,	  in	  discussions	  of	  pharmacological	  use	  of	  gold,	  whether	  for	  tuberculosis	  (unsuccessfully,	  in	  1934)	  or	  rheumatoid	  arthritis	  (successfully,	  in	  1937).	  It	  first	  appeared	  in	  NEJM	  in	  1933,	  in	  a	  humorous	  riff	  by	  Harvey	  Cushing	  about	  the	  state	  of	  surgery	  and	  dentistry	  in	  the	  United	  States.	  The	  next	  five	  references,	  through	  1959,	  all	  referred	  to	  the	  financial	  gold	  standard.	  	   However,	  the	  financial	  gold	  standard	  was	  rarely	  seen	  as	  a	  “gold	  standard.”	  Instead	  it	  proved	  controversial	  for	  much	  of	  its	  history.	  Isaac	  Newton	  put	  Britain	  on	  a	  gold	  standard	  in	  1717,	  an	  arrangement	  formalized	  by	  the	  Royal	  Mint	  in	  1816.	  Many	  other	  countries	  followed	  suit.	  The	  system	  broke	  down	  during	  the	  economic	  turmoil	  of	  the	  early	  twentieth	  century.	  Inflation	  during	  World	  War	  I	  forced	  England	  and	  other	  countries	  off	  the	  gold	  standard.	  A	  variant	  was	  restored	  in	  1925,	  but	  that	  too	  had	  to	  be	  abandoned	  in	  1931	  during	  the	  Great	  Depression.	  After	  preliminary	  moves	  by	  the	  United	  States	  in	  the	  1930s,	  Richard	  Nixon	  finally	  took	  the	  U.S.	  off	  its	  gold	  standard	  in	  1971.	  In	  1976	  the	  U.S.	  government	  revised	  its	  definition	  of	  the	  dollar	  to	  remove	  all	  references	  to	  gold.	  	   It	  was,	  ironically,	  in	  this	  setting	  –	  of	  the	  final	  abandonment	  of	  the	  financial	  gold	  standard	  in	  the	  U.S.	  –	  that	  the	  phrase	  began	  to	  appear	  in	  Lancet	  and	  NEJM	  as	  something	  valuable,	  not	  merely	  as	  a	  standard	  of	  exchange	  but	  as	  the	  definitive	  exemplar	  of	  quality	  and	  reliability.	  A	  1975	  Lancet	  review	  of	  new	  diagnostic	  criteria	  described	  how	  they	  set	  the	  “gold	  standard,”	  providing	  a	  new	  “esperanto	  of	  liver	  disease.”	  In	  NEJM	  in	  1979	  Victor	  McKusick	  described	  the	  presentations	  given	  by	  residents	  at	  Grand	  Rounds	  at	  John	  Hopkins	  as	  the	  “gold	  standard”	  for	  medical	  communication.	  Book	  reviewers	  described	  new	  textbooks	  as	  the	  “gold	  standard”	  for	  their	  fields.	  By	  the	  early	  1980s,	  clinical	  researchers	  described	  specific	  procedures	  as	  the	  diagnostic	  or	  therapeutic	  gold	  standard	  (e.g.,	  adrenal	  vein	  catheterization	  in	  Lancet	  in	  1980,	  cardiac	  catheterization	  in	  NEJM	  in	  1981,	  or	  hemodialysis	  in	  Lancet	  in	  1982).	  After	  the	  first	  occurrence	  in	  1982	  of	  gold	  standard	  in	  association	  with	  RCTs,	  the	  phrase	  became	  commonplace,	  appearing	  less	  often	  within	  quotation	  marks,	  and	  paralleling	  the	  rise	  of	  the	  term	  “evidence-­‐based	  medicine,”	  which	  first	  appeared	  in	  the	  medical	  literature	  in	  1991.	  	   What	  can	  we	  make	  of	  the	  irony	  of	  this	  usage	  entering	  medicine	  in	  the	  years	  after	  it	  was	  abandoned	  as	  a	  tool	  of	  international	  finance	  in	  the	  1970s?	  It	  appeared	  in	  diverse	  therapeutic	  and	  diagnostic	  contexts,	  reflecting	  the	  broad	  aspirations	  in	  medicine	  for	  evidentiary	  solid	  ground	  and	  standardization	  throughout	  this	  era.	  But	  many	  of	  its	  uses	  in	  relation	  to	  RCTs	  were	  critiques,	  reflecting	  a	  legacy	  of	  the	  controversies	  that	  had	  long	  ensnared	  those	  who	  would	  claim	  the	  epistemic	  hegemony	  of	  RCTs.	  The	  debates	  about	  RCTs,	  and	  about	  the	  notion	  of	  medical	  “gold	  standard”	  more	  generally,	  often	  took	  on	  religious	  overtones.	  Angry	  about	  cardiologists’	  demands	  that	  coronary	  artery	  bypass	  grafting	  be	  subjected	  to	  RCTs,	  Lawrence	  Bonchek	  encouraged	  surgeons	  in	  1979	  to	  “resist	  the	  almost	  religious	  fervor	  of	  those	  who	  would	  sanctify	  randomized	  studies	  as	  the	  only	  means	  of	  learning	  the	  truth.”	  Writing	  in	  1992,	  P.	  Finbarr	  Duggan	  complained	  that	  the	  phrase	  “gold	  standard”	  itself	  “smacks	  of	  dogma”	  and	  should	  be	  abandoned.	  	   The	  religious	  language	  here	  may	  not	  be	  coincidental.	  Arthur	  Kleinman	  and	  others	  have	  argued	  that	  the	  emergence	  of	  biomedicine	  within	  the	  monotheistic	  traditions	  of	  Europe	  and	  the	  Middle	  East	  imbued	  medicine	  with	  a	  commitment	  to	  universal	  truths,	  unitary	  paradigms,	  and	  a	  “single-­‐minded	  approach	  to	  illness	  and	  care.”	  The	  idea	  of	  a	  gold	  standard,	  that	  there	  is	  one	  best	  way	  to	  do	  something,	  whether	  conduct	  clinical	  research,	  diagnose	  a	  disease,	  or	  treat	  a	  patient,	  emerges	  from	  this	  underlying	  commitment.	  While	  the	  
desire	  to	  base	  clinical	  decisions	  on	  the	  best	  possible	  evidence	  reflects	  a	  genuine	  effort	  to	  improve	  the	  quality	  of	  medical	  care,	  commitment	  to	  a	  gold	  standard	  does	  more	  than	  that.	  Allegiance	  to	  a	  single	  approach	  provides	  a	  focus	  around	  which	  communities	  can	  organize	  and	  rally.	  But	  critics	  have	  pointed	  to	  the	  dangers	  of	  such	  medical	  monotheism.	  As	  pioneering	  cardiac	  surgeon	  René	  Favaloro	  wrote	  in	  1998,	  reflecting	  on	  three	  decades	  of	  debate	  about	  bypass	  grafting,	  “Randomized	  trials	  have	  developed	  such	  high	  scientific	  stature	  and	  acceptance	  that	  they	  are	  accorded	  an	  almost	  religious	  sanctification	  ...	  If	  relied	  on	  exclusively	  they	  may	  be	  dangerous.”	  Quoting	  Feinstein,	  Favaloro	  argued	  that	  medical	  decisions	  often	  had	  to	  be	  made	  without	  guidance	  from	  clinical	  trials:	  “’To	  acknowledge	  this	  reality	  requires	  no	  loss	  of	  reverence,	  allegiance,	  or	  respect	  for	  the	  primacy	  of	  randomized	  trials	  as	  a	  ‘gold	  standard’	  in	  scientific	  research.’”	  While	  Favaloro	  saw	  this	  as	  a	  particular	  challenge	  for	  surgery,	  physicians	  in	  all	  specialties	  have	  oft-­‐times	  resented	  the	  yoke	  of	  evidence-­‐based	  medicine.	  	   The	  past	  several	  years	  have	  seen	  increasing	  calls	  for	  an	  ecumenical	  approach	  to	  clinical	  research,	  with	  more	  flexible	  standards	  for	  what	  counts	  as	  acceptable	  study	  designs.	  Physicians	  have	  developed	  new	  methods	  to	  extract	  robust	  analyses	  from	  patient	  registries	  and	  from	  the	  ever-­‐growing	  databases	  provided	  by	  electronic	  medical	  records.	  Will	  this	  erode	  the	  status	  of	  RCTs	  as	  a	  gold	  standard?	  The	  rise	  of	  personalized	  medicine,	  meanwhile,	  might	  make	  it	  more	  difficult	  to	  defend	  gold	  standards	  in	  diagnostic	  and	  therapeutic	  practice.	  Personalized	  medicine	  refocuses	  clinical	  attention	  away	  from	  the	  ‘typical’	  patients	  analyzed	  by	  RCTs	  and	  onto	  the	  idiosyncrasies,	  genetic	  or	  otherwise,	  of	  individual	  patients.	  Has	  the	  phrase	  outlived	  its	  usefulness	  in	  medicine?	  It	  is	  too	  soon	  to	  tell.	  Yet	  even	  as	  some	  physicians	  turn	  away	  from	  their	  commitment	  to	  medical	  gold	  standards,	  some	  politicians,	  newly	  wary	  about	  global	  financial	  turbulence,	  talk	  of	  restoring	  the	  financial	  gold	  standard.	  Gold	  standards,	  whether	  actual	  or	  figurative,	  represent	  structures	  of	  exchange	  and	  aspirations	  toward	  stability,	  despite	  developments	  that	  threaten	  both.	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